Please assess the completion status of the following clinical trial:

Trial Title: A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed solid tumors documented as advanced or metastatic disease;~2. Subjects must be considered relapsed or refractory to standard therapies, have been intolerant to standard therapies, or have refused standard therapy;~3. ECOG: 0-1;~4. Adequate organ and bone marrow function;~5. sign an informed consent.~Exclusion Criteria:~1. Patients with brain malignant tumor or active CNS metastasis;~2. UGT1A1\*28 homozygous mutants;~3. Clinically significant GI disorders;~4. Significant cardiovascular disease;~5. Active infection or uncontrolled fever;~6. Pregnant or breast feeding patients;~7. Allergic to a drug ingredient or component;~8. The investigators determined that other conditions were inappropriate for participation in this clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group: (Type: EXPERIMENTAL): Irinotecan liposome plus 5-fluorouracil, Leucovorin

Based on this trial design, predict the completion outcome and termination type (if applicable).